Adding durvalumab and bevacizumab to transarterial chemoembolization improved responses and progression-free survival.
Prof James Catto from the University of Sheffield described the findings as a "major breakthrough" in treating bladder cancer ...
The NRG-HN004 trial showed that durvalumab did not improve outcomes vs cetuximab in locoregionally advanced head and neck ...
The study found that patients with muscle-invasive bladder cancer had significantly less risk of cancer progressing or ...
Overall survival at two years was 82.2% in the durvalumab group and 75.2% in the comparator group. Durvalumab (brand name ...
A phase 3 clinical trial has shown that patients were 32 per cent less likely to experience cancer recurrence when treated ...
A major clinical trial, led by the University of Sheffield, has revealed survival rates for patients with operable bladder ...
The landscape of rare diseases is constantly changing as new ailments and conditions are identified and reported regularly.
According to Bladder Cancer UK, the main symptoms of bladder cancer are: ...
The study found that patients with muscle-invasive bladder cancer had significantly less risk of cancer progressing or returning when treated with immunosurpressant drug durvalumab, and were more ...
Durvalumab is under clinical development by AstraZeneca and currently in Phase II for Neuroendocrine Carcinoma.
Patients with advanced (muscle-invasive) bladder cancer had significantly less risk of cancer progressing or returning when treated with durvalumab, and were more likely to still be alive two ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback